Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230021/S003

Duo Venous Stent System

Philips Image Guided Therapy Corporation · Decision date Feb 12, 2026

FDA DECISIONP230021/S003

What did the FDA approve?

FDA records P230021/S003 as a supplement to PMA P230021, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Feb 12, 2026.

FDA approval order statement

Approval of the updated Instruction for Use for both the Duo Venous Stent System (Pin/Pull delivery system) and Duo Venous Stent System (Triaxial Handle delivery system) with final results of the VIVID study.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Feb 12, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230021/S003
Regulatory pathway
PMA supplement
Product code
QAN
Decision code
APPR
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, iliac vein.

Product code
QAN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230021/S003 received

    Application receipt date recorded by FDA.

  2. P230021/S002 · Related supplement

    Duo Venous Stent System

  3. P230021/S003 · FDA decision

    Normal 180 Day Track No User Fee

  4. P230021/S004 · Related supplement

    Duo Venous Stent System

Timeline entries are records held by MedtechLedger for P230021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230021

Product / regulatory recordCompanyPathwayDecision dateSource
Philips Image Guided Therapy CorporationPMA supplementNov 18, 2025FDA
Philips Image Guided Therapy CorporationPMA supplementAug 26, 2026FDA

Explore the linked device profile

Other records with product code QAN

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA supplementOct 30, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 16, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementJun 10, 2026FDA
Medtronic Vascular, Inc.PMA supplementApr 27, 2026FDA
Cook Ireland, Ltd.PMA supplementApr 14, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Philips Image Guided Therapy Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5905 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records